Analysts predict results in upper end of Lundbeck's expectations ahead of financial report

Analysts are busy speculating over Lundbeck's 2021 prognosis before the quarterly report is released on Wednesday. They predict revenue of just under DKK 16.5bn (USD 2.6bn), and operating profits of DKK 2262m (USD 352m).

Deborah Dunsire, CEO at Lundbeck | Photo: Gregers Tycho/ERH

Estimates are already in the high end of Lundbeck's own prognosis in the prelude to the company's third quarter results, which will be released on Wednesday morning.

Analysts will be paying close attention to four of Lundbeck's key products: the antidepressant Brintellix; the schizophrenia drug Abilify Maintena; Rexulti, which is used in schizophrenia and depression treatments; and Veypti, a migraine preventive therapy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs